Skip to main content
SpringerLink
Log in

The Activity of Medroxyprogesterone Acetate, an Androgenic Ligand, in Ovarian Cancer Cell Invasion

  • Original Article
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Objectives: An epithelial ovarian cancer cell line constitutively expressing the androgen receptor was created to evaluate the mechanism and effects of androgen receptor activation on epithelial ovarian cancer cell invasion. Methods: Immunocytochemistry and Western blot analyses confirmed androgen receptor expression. Boyden chamber invasion assays were performed using cells treated with the androgen receptor ligands medroxyprogesterone acetate or dihydrotestosterone. The matrix metalloproteinases associated with invasion were investigated using zymographic assays. Results: Androgen receptor—mediated invasion is ligand dependent. While both medroxyprogesterone acetate and dihydrotestosterone signal through androgen receptor, medroxyprogesterone acetate is more effective at stimulating invasion of epithelial ovarian cancer cells. Unlike the wild-type epithelial ovarian cancer cells, this increase in invasion in androgen receptor+ epithelial ovarian cancer cells does not seem to be dependent on matrix metalloproteinase 2 or 9 activation. Conclusion: Although classified as a progestin, medroxyprogesterone acetate has significant androgenic activity unique from the pure androgen dihydrotestosterone. Our studies suggest that pharmacologic doses of medroxyprogesterone acetate may actually increase the invasive potential of epithelial ovarian cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 1987;316:650–655.

  2. Risch HA Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90:1774–1786.

    Article  CAS  Google Scholar 

  3. Kuhnel R., de Graaff J., Rao BR, Stolk JG Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem. 1987;26:393–397.

    Article  CAS  Google Scholar 

  4. Li AJ, Baldwin RL, Karlan BY Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res. 2003;9:3667–3673.

    CAS  PubMed  Google Scholar 

  5. Edmondson R., Monaghan J., Davies B. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer. 2002;86:879–885.

    Article  CAS  PubMed Central  Google Scholar 

  6. Syed V., Ulinski G., Mok S., Yiu G., Ho S. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 2001;61:6768–6776.

    CAS  PubMed  Google Scholar 

  7. Kemppainen JA, Langley E., Wong CI, Bobseine K., Kelce WR, Wilson EM Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol. 1999;13:440–454.

    Article  CAS  Google Scholar 

  8. Ghatge RP, Jacobsen BM, Schittone SA, Horwitz KB The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res. 2005;7: R1036–R1050.

    Article  CAS  PubMed Central  Google Scholar 

  9. Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14:357–361.

    Article  CAS  Google Scholar 

  10. Miller AA, Becher R., Schmidt CG Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer. J Cancer Res Clin Oncol. 1988;114:186–190.

    Article  CAS  Google Scholar 

  11. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736–1744.

    Article  CAS  Google Scholar 

  12. Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol. 1995;13:1572–1577.

    Article  CAS  Google Scholar 

  13. Recchione C., Venturelli E., Manzari A., Cavalleri A., Martinetti A., Secreto G. Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol. 1995;52:541–546.

    Article  CAS  Google Scholar 

  14. Horwitz KB, Pike AW, Gonzalez-Aller C., Fennessey PV Progesterone metabolism in T47Dco human breast cancer cells-II. Intracellular metabolic path of progesterone and synthetic progestins. J Steroid Biochem. 1986;25:911–916.

    Article  CAS  Google Scholar 

  15. Fishman DA, Bafetti LM, Stack MS Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis. 1996;16:150–159.

    CAS  PubMed  Google Scholar 

  16. Fishman DA, Liu Y., Ellerbroek SM, Stack MS Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 2001;61:3194–3199.

    CAS  PubMed  Google Scholar 

  17. Wang FQ, So J., Reierstad S., Fishman DA Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005;114:19–31.

    Article  CAS  Google Scholar 

  18. Liao X., Thrasher J., Pelling J., Holzbeierlein J., Sang Q., Li B. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology. 2003;144:1656–1663.

    Article  CAS  Google Scholar 

  19. Simental JA, Sar M., Lane MV, French FS, Wilson EM Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem. 1991;266:510–518.

    CAS  PubMed  Google Scholar 

  20. Richer JK, Lange CA, Manning NG, Owen G., Powell R., Horwitz KB Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem. 1998;273:31317–31326.

    Article  CAS  Google Scholar 

  21. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. Jama. 1995;274:1926–1930.

    Article  CAS  Google Scholar 

  22. Kemppainen JA, Lane MV, Sar M., Wilson EM Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem. 1992;267:968–974.

    CAS  PubMed  Google Scholar 

  23. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736–1744.

    Article  CAS  Google Scholar 

  24. Hamerlynck JV, Maskens AP, Mangioni C., et al. Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study. Gynecol Oncol. 1985;22:313–316.

    Article  CAS  Google Scholar 

  25. Tumolo S., Rao BR, van der Burg ME, Guastalla JP, Renard J., Vermorken JB Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer. 1994;30A:911–914.

    Article  CAS  Google Scholar 

  26. Birrell S., Butler L., Harris J., Buchanan G. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB. 2007;21:2285–2293.

    Article  CAS  Google Scholar 

  27. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21:865–883.

    Article  CAS  Google Scholar 

  28. Saner KJ, Welter BH, Zhang F., et al. Cloning and expression of a novel, truncated, progesterone receptor. Mol Cell Endocrinol. 2003;200:155–163.

    Article  CAS  Google Scholar 

  29. So J., Wang FQ, Navari J., Schreher J., Fishman DA LPAinduced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol. 2005;97:870–878.

    Article  CAS  Google Scholar 

  30. Ariztia EV, Lee CJ, Gogoi R., Fishman DA The tumor microenvironment: key to early detection. Crit Rev Clin Lab Sci. 2006;43:393–425.

    Article  CAS  Google Scholar 

  31. Rabbani S., Mazar A. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am. 2001;10:393–415.

    Article  CAS  Google Scholar 

  32. Di Nezza LA, Jobling T., Salamonsen LA Progestin suppresses matrix metalloproteinase production in endometrial cancer. Gynecol Oncol. 2003;89:325–333.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, New York University, 550 First Avenue, TCH-528, New York, New York, 10016, USA

    Radhika Gogoi MD, PhD, Marek Kudla MD, Orlando Gil PhD & David Fishman MD

Authors
  1. Radhika Gogoi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marek Kudla MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Orlando Gil PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Fishman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Fishman MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gogoi, R., Kudla, M., Gil, O. et al. The Activity of Medroxyprogesterone Acetate, an Androgenic Ligand, in Ovarian Cancer Cell Invasion. Reprod. Sci. 15, 846–852 (2008). https://doi.org/10.1177/1933719108323446

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1933719108323446

Key words

Search

Navigation